IL2 and neoplasm: In a B16-F10 melanoma mouse model, treatment with high and intermediate doses of IL-2 inhibited tumor outgrowth compared to placebo, but treatment with low−dose IL-2 allowed more tumor outgrowth than the placebo (10).